April 5, 2022, Vol 327, No. 13, Pages 1209-1300
Caring for the Critically Ill Patient
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19A Randomized Clinical Trial
REMAP-CAP Writing Committee for the REMAP-CAP Investigators
free access has active quiz
JAMA. 2022;327(13):1247-1259. doi:10.1001/jama.2022.2910
This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care unit respiratory or cardiovascular organ support within 21 days among patients critically ill with COVID-19.